---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-119406"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T10:28:53.442443+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IO Biotech Q1 net loss $22.4M; Phase 3 melanoma vaccine readout on track for Q3 2025

## Summary
- Net loss of $22.4M in Q1 2025 vs $19.5M in Q1 2024; R&D expenses rose to $16.4M.
- Cash and equivalents $37.1M at March 31, 2025, down from $60.0M at Dec 31, 2024; Q1 cash burn $22.9M.
- Drew €10.0M tranche A of EIB loan on May 6; believes conditions met for €12.5M second tranche.
- Phase 3 trial primary endpoint (PFS) readout on track for Q3 2025; BLA submission planned in 2025.
- Enrollment completed in Phase 2 basket trial (IOB-032) for SCCHN/melanoma; initial data expected H2 2025.

## SEC filing metadata
- accession: 0001193125-25-119406
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312525119406/0001193125-25-119406-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312525119406/d859516d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-119406
- JSON: https://secwatch.observer/filing/0001193125-25-119406.json
- Plain text: https://secwatch.observer/filing/0001193125-25-119406.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.